SAN FRANCISCO and WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) — Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that members of management, will participate in a fireside chat at the Stifel 2024 Immunology and Inflammation Summit on Wednesday, September 18, 2024 at 12:30 p.m. E.T. / 9:30 a.m. P.T.
A live and archived webcast of the fireside chat and presentation will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.
About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. APG777, the company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets. With four validated targets in its portfolio, Apogee is seeking to achieve best in class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit www.apogeetherapeutics.com.
Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
noel.kurdi@apogeetherapeutics.com
Media Contact:
Dan Budwick
1AB
dan@1abmedia.com
MILWAUKEE--(BUSINESS WIRE)--#assistedliving--ECP, the leading software platform purpose-built for assisted living, announced today a significant growth…
Believes Belated Go-Shop Process Fails to Cure Fundamental Flaws in the Transaction’s Process, Timing, and…
Collaboration Advances CMS Health Tech Ecosystem Goals by Enabling Seamless, Secure Access to Health Data…
DALLAS, Dec. 4, 2025 /PRNewswire/ -- Both Ends Believing (BEB), a Dallas-based global nonprofit with…
Skilled brings wireless-first nurse call, real-time insights, and integrated workflows, completing Sage Core's support across…
NEW YORK, Dec. 8, 2025 /PRNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF)…